Vaginal Ring Market Scope
Vaginal rings or V-ring (polymeric drug) are the devices which are placed inside the vagina and provide continuous doses of estrogen and progestogen into the bloodstream to prevent pregnancy. V rings also have non-contraceptive applications such as symptomatic relief during menopause and management of hormonal imbalance in individuals with polycystic ovary syndrome (PCOS). Polycystic ovary syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Further, the rising prevalence of disease related to women’s health and increasing initiatives of the government to support women’s health is driving the vaginal ring market.
According to AMA, the Global Vaginal Ring market is expected to see growth rate of 2.98%
The Global Vaginal Ring market is moderately fragmented with companies focusing on following several marketing strategies for creating awareness among the consumers about the several advantages of vaginal rings. Several leading brands have increased their marketing expenditure for maintaining their leading positions in the market. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Vaginal Ring market throughout the predicted period.
Bayer AG (Germany), Merck & Co., Inc. (United States), Ansell (Australia), Pfizer Inc. (United States), Actavis (United States), Allergan plc (Ireland), HRA Pharma SA (France), Eurogine (Spain), Yantai JiShengYaoXie (China), TianYi (China), Merck & Co., Inc (United States), Johnson & Johnson (United States) and QPharma AB (Sweden ) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are SMB Corporation of India (India), Shenyang Liren (China), H & J Medical (United States) and Novo Nordisk Ltd (India).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
The study have segmented the market of Global Vaginal Ring market by Type (Estring, Femring and NuvaRing), by Application (Contraception, Menopause Vasomotor Symptoms, Polycystic Ovarian Syndrome (PCOs) and Others) and Region with country level break-up.
On the basis of geography, the market of Vaginal Ring has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In January 2019, clinical trial study conducted by Medical press company The Phase I study, known as MTN-038, is being conducted by researchers from the National Institutes of Health-funded Microbicide Trials Network (MTN) at three United States. Trial sites. The vaginal ring being evaluated in the study contains an antiretroviral (ARV) drug called Tenofovir, a mainstay drug used in the treatment of HIV.
In August 2018, The Food and Drug Administration approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year. Annovera is a reusable donut-shaped (ring), non-biodegradable, a flexible vaginal system that is placed in the vagina for three weeks followed by one week out of the vagina, at which time women may experience a period (a withdrawal bleed). This schedule is repeated every four weeks for one year (thirteen 28-day menstrual cycles).
- Increasing Awareness among Women Regarding use of Contraceptives Leading to Increase in End-users
- Growing Healthcare Industry and Increasing Population of Geriatric Women Population
- Growing Importance of Family Planning
- Rising Prevalence of Disease Related to Women’s Health
- Increasing Progressive Outlook on Premarital Sex
- Increasing Investment by the Government to Enhance Healthcare Facilities
- Probability of Developing Breast Cancer by the use of Vaginal Ring among Women
- Adverse Reaction of Vaginal Rings among Some Female Population
Key Target Audience
Vaginal Ring Manufacturers, Healthcare Industry, Potential Investors, Government & Regulatory Bodies, Pharmaceutical Companies and Others